I am honored to have created and now lead Prapela, America's most-awarded Pediatric Medical Device startup. At Prapela, we focus on our non-invasive stimulation therapy to improve breathing and oxygenation in newborns. Harvard's Wyss Institute for Biologically Inspired Engineering, the University of Massachusetts Medical School, and Massachusetts General Hospital spent over ten years developing and evaluating our precise stimulation. Since 2018, Prapela has received two FDA breakthrough device designations and four grants from the NIH. We are preparing a direct De Novo submission to the FDA to improve the treatment of opioid-exposed newborns - our first indication. Our most recent breakthrough device designation is to reduce apnea in preterm newborns. Our most recent project aims to minimize hypoxemia in early preterm newborns. Prapela has received $8.45M, with 97% coming from "equity-free" awards and grants. We're grateful for the recognition from the NIH, especially NIDA, the FDA, Ohio, Massachusetts, Maine, Johnson & Johnson, Children's National Hospital, Texas Children's Hospital, Finland, and the Charles H. Hood Foundation. We are on a journey to help improve the health of every newborn.Previously, five of the Top 25 Medical Device companies in the world trusted me in leadership and executive roles. I led or assisted in generating over $5.4 billion in revenue and launched over 100 new products. My experience includes work in Medical devices, Diagnostics, Medical Imaging, Durable Medical Equipment, Biologics, Wearables, Genetic testing, and Consumer products markets. I have worked closely with physicians, nurses, therapists, and leaders in Neonatology, Orthopedics, Pain Management, OB/GYN, and Cardiology specialties. As a 2X CEO, my operational experience includes general management, marketing, sales, finance, HR, operations, R&D/product development, clinical research, quality, and regulatory affairs. I am the Principal Investigator of our NIH/NIDA Phase II SBIR research into opioid-exposed newborns and a Fast-Track SBIR grant to reduce apneic events. More recently, we received 1st place and $50,000 in the MedTech Innovator/Children's National Hospital program for Pediatric Innovation.